-
Indicted Raul Castro reappears after months out of public view
-
Israel reopens once-closed West Bank settlement
-
Italian teen Curtis breaks women's 50m backstroke world record for second time
-
Taylor to captain New Zealand for first time against Bulls
-
Taulagi steps out of 'comfort zone' with code switch to French Top 14 new boys
-
Carrick urges Man Utd to push for more signings to boost title bid
-
Leicester's Thai owners put troubled club up for sale: reports
-
'This was my World Cup' says Somali ref after UEFA Super Cup
-
Stocks steady as US inflation worries ease, oil slips
-
Survivors tell of horror of Zimbabwe ferry sinking as death toll hits 46
-
Porsche to end production of flagship electric car: report
-
Juventus forward Vlahovic signs three-year Besiktas deal
-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
-
Blaze forces families to abandon Turkish tour boat
-
Stocks gain as US inflation worries ease, oil slips
-
'If you can, move!' say Rome's viral dancing seniors
-
Heavy rain soaks eastern Japan, prompting highest-level warning
-
Zambia voters weigh Hichilema's economic record
-
Celtic boss O'Neill 'much better' after hospital procedure
-
SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026
-
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
-
Hodgkinson sets up Werro showdown after Euro 800m drama
-
Maghreb sees demographic shift with fertility at historic low
-
'How many will die?': the mysterious ailment killing Kenyan elephants
-
European stocks gain as oil prices ease
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
US regulator approves new generic abortion pill, conservatives outraged
US regulators have approved an additional generic version of the abortion pill mifepristone, a normally routine move that nevertheless angered anti-abortion activists.
A number of conservative figures and anti-abortion groups decried the regulatory step, with the institution Students for Life Action calling it "a stain on the Trump presidency."
The drugmaker Evita said on its website the US Food and Drug Administration had this week approved the company's generic tablet, which is currently approved to end pregnancies up to 70 days of gestation.
The medication is used in the majority of abortions in the United States, and also routinely used for managing early miscarriage.
The FDA originally approved mifepristone in 2000, and another generic already exists.
Approvals of additional generics are typically routine.
But Marjorie Dannenfelser, president of the organization Susan B. Anthony Pro-Life America, called the approval "reckless" and "unconscionable" in a statement Thursday.
Senator Josh Hawley, a Republican from Missouri, said on X he had "lost confidence" in FDA leadership while former vice president Mike Pence posted it was "a complete betrayal of the pro-life movement that elected President Trump."
Pence also called for the dismissal of Robert F. Kennedy Jr, Trump's controversial health chief.
The ruckus comes weeks after Kennedy and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying the FDA was conducting a new review of mifepristone's safety.
Abortion rights organizations have dubbed that a blatant attempt to undermine health care access, and a coalition of attorneys general from more than a dozen Democratic-led states vowed to protect availability of the drug.
The American Medical Association has called the prescription drug "exceedingly safe and effective" and said restricting access to mifepristone would "jeopardize public health."
That take echoes the positions of many leading medical institutions.
Mifepristone, which prevents pregnancy progression, is generally used in combination with misoprostol, which empties the uterus.
J.Saleh--SF-PST